Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
Open Access
- 8 May 2010
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 30 (5) , 734-745
Abstract
Subcutaneous human IgG (SCIG) therapy in primary immunodeficiency (PID) offers sustained IgG levels throughout the dosing cycle and fewer adverse events (AEs) compared to intravenous immunoglobulin (IVIG). A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized with L-proline. A prospective, open-label, multicenter, single-arm, phase III study evaluated the efficacy and safety of IgPro20 in patients with PID over 15 months. Forty-nine patients (5–72 years) previously treated with IVIG received weekly subcutaneous infusions of IgPro20. The mean serum IgG level was 12.5 g/L. No serious bacterial infections were reported. There were 96 nonserious infections (rate 2.76/patient per year). The rate of days missed from work/school was 2.06/patient per year, and the rate of hospitalization was 0.2/patient per year. Ninety-nine percent of AEs were mild or moderate. No serious, IgPro20-related AEs were reported. IgPro20 effectively protected patients with PID against infections and maintained serum IgG levels without causing unexpected AEs.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and Safety of Privigen in Children and Adolescents With Primary ImmunodeficiencyPediatric Asthma, Allergy & Immunology, 2009
- Investigations of prion and virus safety of a new liquid IVIG productBiologicals, 2008
- Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administrationAnnals of Allergy, Asthma & Immunology, 2007
- Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficienciesCurrent Opinion in Allergy and Clinical Immunology, 2006
- IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of lifeThrombosis and Haemostasis, 2004
- Express Subcutaneous IgG Infusions: Decreased Time of Delivery with Maintained SafetyClinical Immunology, 2002
- Common Variable Immunodeficiency: Clinical and Immunological Features of 248 PatientsClinical Immunology, 1999
- Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product☆☆☆★Journal of Allergy and Clinical Immunology, 1998
- Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costsThe Lancet, 1995
- Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusionThe Lancet, 1991